Table 2.
Associated factors of memory complaints in study participants (n = 401).
| Unadjusted OR | p value | 95% CI | Adjusted OR | p value | 95% CI | |
|---|---|---|---|---|---|---|
| Age (years) | 0.999 | 0.909 | 0.982 to 1.017 | 1.011 | 0.365 | 0.987 to 1.037 |
| Sex | ||||||
| Female | ref. | ref. | ||||
| Male | 1.005 | 0.984 | 0.597 to 1.692 | 1.031 | 0.916 | 0.589 to 1.804 |
| Region | ||||||
| Urban | ref. | ref. | ||||
| Rural | 2.461 | 0.01* | 1.246 to 4.862 | 3.635 | 0.001* | 1.722 to 7.675 |
| COVID-19 severity | ||||||
| Mild & moderate | ref. | ref. | ||||
| Severe | 0.665 | 0.209 | 0.352 to 1.256 | 0.49 | 0.362 | 0.105 to 2.275 |
| Critical | 0.697 | 0.293 | 0.356 to 1.366 | 0.5 | 0.438 | 0.087 to 2.881 |
| Duration since COVID-19 recovery | ||||||
| 3–6 months | ref. | ref. | ||||
| 6–12 months | 1.837s | 0.032* | 1.054 to 3.204 | 6.656 | 0.033* | 1.16 to 38.18 |
| Oxygen needed | 0.596 | 0.059 | 0.349 to 1.019 | 1.074 | 0.938 | 0.176 to 6.545 |
| Hospitalized | 0.876 | 0.601 | 0.532 to 1.442 | 2.194 | 0.18 | 0.696 to 6.916 |
| Treatment modalities | ||||||
| Antibiotics | 1.51 | 0.111 | 0.909 to 2.507 | 1.324 | 0.418 | 0.671 to 2.61 |
| Anticoagulant | 0.946 | 0.844 | 0.542 to 1.65 | 2.471 | 0.111 | 0.811 to 7.531 |
| Steroids | 1.658 | 0.05 | 1.001 to 2.748 | 1.253 | 0.506 | 0.645 to 2.433 |
| Tocilizumab | 1.053 | 0.964 | 0.116 to 9.553 | 1.219 | 0.866 | 0.123 to 12.116 |
| Antiviral | 0.892 | 0.751 | 0.441 to 1.805 | 0.931 | 0.863 | 0.415 to 2.092 |
| Co-morbidities | ||||||
| HTN | 1.228 | 0.482 | 0.693 to 2.178 | 1.509 | 0.284 | 0.711 to 3.203 |
| DM | 1.107 | 0.736 | 0.613 to 1.998 | 1.124 | 0.766 | 0.52 to 2.433 |
| CKD | 0.839 | 0.874 | 0.097 to 7.291 | 0.512 | 0.564 | 0.053 to 4.978 |
| COPD | 4.384 | 0.04* | 1.071 to 17.937 | 2.926 | 0.17 | 0.632 to 13.543 |
OR, odds ratio; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.
*
p value <0.05.